ask="13.64"
ask_size="100"
average_daily_volume="36015"
bid="11.00"
bid_size="300"
book_value="5.24"
change="+0.30"
change_from_200_day_moving_average="-5.87"
change_from_50_day_moving_average="-2.22"
change_from_52_week_high="-13.27"
change_From_52_week_low="3.07"
change_in_percent="+2.35%"
close="13.09"
dividend_pay_date="N/A"
dividend_per_share="N/A"
dividend_yield="N/A"
earnings_per_share="-5.80"
ebitda="-32.35M"
eps_estimate_current_year="N/A"
eps_estimate_next_quarter="-0.62"
eps_estimate_next_year="0.46"
ex_dividend_date="N/A"
float_shares="7111000"
high="13.61"
high_52_weeks="26.36"
last_trade_date="3/17/2017"
last_trade_price="13.09"
last_trade_size="2067"
last_trade_time="4:00pm"
low="12.37"
low_52_weeks="10.02"
market_capitalization="219.74M"
moving_average_200_day="18.96"
moving_average_50_day="15.31"
name="Protagonist Therapeutics
Inc."
notes="N/A"
one_year_target_price="31.00"
open="12.62"
pe_ratio="N/A"
peg_ratio="0.00"
percent_change_from_200_day_moving_average="-30.97%"
percent_change_from_50_day_moving_average="-14.49%"
percent_change_from_52_week_high="-50.34%"
percent_change_from_52_week_low="+30.64%"
previous_close="12.79"
price_eps_estimate_current_year="N/A"
price_eps_Estimate_next_year="28.46"
price_per_book="2.44"
price_per_sales="N/A"
revenue="N/A"
shares_outstanding="16787000"
short_ratio="6.28"
stock_exchange="NGM"
symbol="PTGX"
volume="46809"
weeks_range_52="10.02 - 26.36"
